News

Intra-Cellular Therapies Highlights Lumateperone Presentations at the 59th Annual Meeting of the American College of Neuropsychopharmacology

Presentations highlight lumateperone’s broad antidepressant effects in patients with bipolar disorder and in patients with schizophrenia with co-morbid depression NEW...

Prothena Reports Positive 9 Month Results from Phase 1 Long-term Extension Study of PRX004, the First Investigational Anti-Amyloid Immunotherapy for the Treatment of ATTR Amyloidosis

RA Capital Management Leads $45M Series A Financing for PepGen’s Next-Generation Oligonucleotide Platform Targeting Duchenne Muscular Dystrophy and Other Rare Neuromuscular and Cardiac Diseases

PepGen’s proprietary cell-penetrating peptide technology promises enhanced safety, efficacy, and improved delivery to cardiac muscle; Oxford Sciences Innovation, The University...

VitalHub Announces Addition of Award-Winning Synopsis iQ to Recently Expanded Multi-Year Licensing Deal with King’s College Hospital NHS Foundation Trust

TORONTO, Dec. 09, 2020 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSXV: VHI) is pleased to announce the...

error: Content is protected !!